Ligand Pharmaceuticals Trump Street View Third Quarter Results Supports Full Year Outlook; Equities up 5%

(RTTNews) – Shares of Ligand Pharmaceuticals Inc. (LGND) gained 5% during extended trading hours Tuesday after the company’s third-quarter earnings and earnings beat Wall Street estimates. The company also reaffirmed its outlook for the full year.

Third quarter net income was $ 13.7 million or $ 0.80 per share, compared with a net loss of $ 6.7 million or $ 0.42 per share last year.

On an adjusted basis, net income was $ 27.1 million or $ 1.58 per share, compared to $ 17.5 million or $ 1.04 per share last year.

Third quarter revenue reached $ 64.8 million from $ 41.8 million last year.

Analysts polled by Thomson Reuters expected earnings of $ 1.04 per share on revenue of $ 55.65 million for the quarter. Analysts’ estimates generally exclude one-time items.

Ligand reaffirmed its financial guidance for 2021. Ligand continues to expect total revenue for the year 2021 to be between $ 265 million and $ 275 million, and adjusted profit between 5.80 and 6, 05 dollars per share. Analysts currently estimate earnings of $ 5.93 per share on revenue of $ 270.82 million for the full year.

LGND closed Tuesday’s trading at $ 151.88, down $ 1.94 or 1.26%, on the Nasdaq. The stock, however, gained $ 8.12 or 5.35% in after-hours trading.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

About William Moorhead

Check Also

Mojo Vision smart contact lens: ready for real world testing

It took seven years for Mojo Vision to get where it is today: a complete …

Leave a Reply

Your email address will not be published.